• JCR Pharmaceuticals dosed the first patient in a global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.
• Results have not been presented; the study will generate future safety, tolerability, and early efficacy readouts in children under six.
• Program targets an ultra-rare neurodegenerative disorder with no approved therapies, positioning JR-446 as a potential first-in-class option.
• MEDIPAL holds commercialization rights outside Japan; JCR is running the global trial as sponsor, shaping development timelines and partnering economics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JCR Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609111211BIZWIRE_USPR_____20260911_BW075179) on September 11, 2026, and is solely responsible for the information contained therein.